Page last updated: 2024-08-02 22:15:39

sb 706504

Description

Cross-References

ID SourceID
PubMed CID11853799
SCHEMBL ID4267559
SCHEMBL ID13853009
MeSH IDM0529673

Synonyms (8)

Synonym
SCHEMBL4267559
SCHEMBL13853009
AKOS025142041
n-cyano-n'-[2-[[8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-7,8-dihydro-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]ethyl]guanidine
sb 706504
n-cyano-n'-[2-[[8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-7,8-dihydro-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]ethyl]-guanidine
NCGC00387225-01
1-cyano-2-[2-[[8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]ethyl]guanidine

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (mM)Bioassay(s)
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency0.0849AID1645841
GVesicular stomatitis virusPotency3.0112AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency18.9991AID1645840
Interferon betaHomo sapiens (human)Potency3.0112AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency3.0112AID1645842
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency3.0112AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency3.0112AID1645842

Bioassays (8)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
ISSN: 2472-5560
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
ISSN: 1091-6490
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508591NCATS Rat Liver Microsome Stability Profiling2020Scientific reports, 11-26, Volume: 10, Issue:1
ISSN: 2045-2322
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
AID1508612NCATS Parallel Artificial Membrane Permeability Assay (PAMPA) Profiling2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
ISSN: 1464-3391
Highly predictive and interpretable models for PAMPA permeability.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
ISSN: 1521-0111
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
ISSN: 1091-6490
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
ISSN: 1521-0111
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1645848NCATS Kinetic Aqueous Solubility Profiling2019Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14
ISSN: 1464-3391
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (50.00)24.3611
2020's3 (50.00)2.80

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
b 844-39diarylmethane201720177.0low000010
pk 11195aromatic amide;
isoquinolines;
monocarboxylic acid amide;
monochlorobenzenes
antineoplastic agent201720205.3low000030
jtv519201720205.3high000030
alprazolamorganochlorine compound;
triazolobenzodiazepine
anticonvulsant;
anxiolytic drug;
GABA agonist;
muscle relaxant;
sedative;
xenobiotic
201720205.3low000030
dan 2163aromatic amide;
aromatic amine;
benzamides;
pyrrolidines;
sulfone
environmental contaminant;
second generation antipsychotic;
xenobiotic
201720205.3low000030
amlexanoxmonocarboxylic acid;
pyridochromene
anti-allergic agent;
anti-ulcer drug;
non-steroidal anti-inflammatory drug
201720205.3low000030
astemizolebenzimidazoles;
piperidines
anti-allergic agent;
anticoronaviral agent;
H1-receptor antagonist
201720205.3low000030
benzbromarone1-benzofurans;
aromatic ketone
uricosuric drug201720205.3low000030
bisindolylmaleimide i201720205.3low000030
bufexamacaromatic ether;
hydroxamic acid
antipyretic;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
201720205.3low000030
cadralazineorganic molecular entity201720205.3low000030
carvedilolcarbazoles;
secondary alcohol;
secondary amino compound
alpha-adrenergic antagonist;
antihypertensive agent;
beta-adrenergic antagonist;
cardiovascular drug;
vasodilator agent
201920204.5low000020
cetirizineether;
monocarboxylic acid;
monochlorobenzenes;
piperazines
anti-allergic agent;
environmental contaminant;
H1-receptor antagonist;
xenobiotic
201920204.5low000020
chlorcyclizinediarylmethane201720205.3low000030
ci 994acetamides;
benzamides;
substituted aniline
antineoplastic agent;
EC 3.5.1.98 (histone deacetylase) inhibitor
201720205.3low000030
cyclosporine201720205.5high000020
fenbendazolearyl sulfide;
benzimidazoles;
carbamate ester
antinematodal drug201720205.3low000030
berotekresorcinols;
secondary alcohol;
secondary amino compound
beta-adrenergic agonist;
bronchodilator agent;
sympathomimetic agent;
tocolytic agent
201720177.0low000010
go 6976indolocarbazole;
organic heterohexacyclic compound
EC 2.7.11.13 (protein kinase C) inhibitor201720205.3low000030
haloperidolaromatic ketone;
hydroxypiperidine;
monochlorobenzenes;
organofluorine compound;
tertiary alcohol
antidyskinesia agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist
201720205.3low000030
homochlorocyclizinediarylmethane201720205.3low000030
hydroxyzinehydroxyether;
monochlorobenzenes;
N-alkylpiperazine
anticoronaviral agent;
antipruritic drug;
anxiolytic drug;
dermatologic drug;
H1-receptor antagonist
201720205.3low000030
ifenprodilpiperidines201720205.3low000030
1-(2-naphthalenyl)-3-[(phenylmethyl)-propan-2-ylamino]-1-propanonenaphthalenes201720205.3medium000030
ketaminecyclohexanones;
monochlorobenzenes;
secondary amino compound
analgesic;
environmental contaminant;
intravenous anaesthetic;
neurotoxin;
NMDA receptor antagonist;
xenobiotic
201720205.3low000030
ketoprofenbenzophenones;
oxo monocarboxylic acid
antipyretic;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-steroidal anti-inflammatory drug;
xenobiotic
201720205.3low000030
mebendazolearomatic ketone;
benzimidazoles;
carbamate ester
antinematodal drug;
microtubule-destabilising agent;
tubulin modulator
201720205.3low000030
mephenesinaromatic ether;
glycerol ether
201720205.3low000030
niclosamidebenzamides;
C-nitro compound;
monochlorobenzenes;
salicylanilides;
secondary carboxamide
anthelminthic drug;
anticoronaviral agent;
antiparasitic agent;
apoptosis inducer;
molluscicide;
piscicide;
STAT3 inhibitor
201720205.3low000030
oxibendazolebenzimidazoles;
carbamate ester
201720205.3low000030
4-(2'-methoxyphenyl)-1-(2'-(n-(2''-pyridinyl)-4-iodobenzamido)ethyl)piperazine201720205.3low000030
perphenazineN-(2-hydroxyethyl)piperazine;
N-alkylpiperazine;
organochlorine compound;
phenothiazines
antiemetic;
dopaminergic antagonist;
phenothiazine antipsychotic drug
201720205.3low000030
pimobendanbenzimidazoles;
pyridazinone
cardiotonic drug;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
vasodilator agent
201720205.3low000030
ag 1879aromatic amine;
monochlorobenzenes;
pyrazolopyrimidine
beta-adrenergic antagonist;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
geroprotector
201720205.3low000030
3-[(3,5-dibromo-4-hydroxyphenyl)methylidene]-5-iodo-1H-indol-2-oneindoles201720205.5medium000020
ro 31-8220imidothiocarbamic ester;
indoles;
maleimides
EC 2.7.11.13 (protein kinase C) inhibitor201720205.3low000030
ropiniroleindolones;
tertiary amine
antidyskinesia agent;
antiparkinson drug;
central nervous system drug;
dopamine agonist
201720205.3low000030
vorinostatdicarboxylic acid diamide;
hydroxamic acid
antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
201720205.3low000030
2-[4-(4-chloro-1,2-diphenylbut-1-enyl)phenoxy]-N,N-dimethylethanaminestilbenoid201720205.5high000020
trifluperidolaromatic ketone201720177.0low000010
3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazolearomatic primary alcohol;
furans;
indazoles
antineoplastic agent;
apoptosis inducer;
platelet aggregation inhibitor;
soluble guanylate cyclase activator;
vasodilator agent
201720205.3low000030
zotepinedibenzothiepine;
tertiary amino compound
alpha-adrenergic drug;
second generation antipsychotic;
serotonergic drug
201720205.3low000030
colchicinealkaloid;
colchicine
anti-inflammatory agent;
gout suppressant;
mutagen
201720205.3low000030
benziodaronearomatic ketone201720205.3low000030
cyclizineN-alkylpiperazineantiemetic;
central nervous system depressant;
cholinergic antagonist;
H1-receptor antagonist;
local anaesthetic
201920195.0low000010
trehalosetrehaloseEscherichia coli metabolite;
geroprotector;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
201720205.3low000030
triclocarbandichlorobenzene;
monochlorobenzenes;
phenylureas
antimicrobial agent;
antiseptic drug;
disinfectant;
environmental contaminant;
xenobiotic
201720205.3low000030
4-tert-octylphenolalkylbenzene201720205.3low000030
ethamivanmethoxybenzenes;
phenols
201720205.3low000030
methysergideergoline alkaloid201720205.3low000030
emetineisoquinoline alkaloid;
pyridoisoquinoline
antiamoebic agent;
anticoronaviral agent;
antiinfective agent;
antimalarial;
antineoplastic agent;
antiprotozoal drug;
antiviral agent;
autophagy inhibitor;
emetic;
expectorant;
plant metabolite;
protein synthesis inhibitor
201720205.3low000030
podophyllotoxinfuronaphthodioxole;
lignan;
organic heterotetracyclic compound
antimitotic;
antineoplastic agent;
keratolytic drug;
microtubule-destabilising agent;
plant metabolite;
tubulin modulator
201720205.3low000030
etonitazene201720205.3low000030
clothiapinedibenzothiazepine201720205.3low000030
benperidolaromatic ketone201720205.3low000030
7-hydroxychlorpromazinephenothiazines201720205.3medium000030
camptothecindelta-lactone;
pyranoindolizinoquinoline;
quinoline alkaloid;
tertiary alcohol
antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
genotoxin;
plant metabolite
201720205.3low000030
thenalidinedialkylarylamine;
tertiary amino compound
201720205.3medium000030
bromocriptineindole alkaloidantidyskinesia agent;
antiparkinson drug;
dopamine agonist;
hormone antagonist
201720205.3low000030
dexchlorpheniraminechlorphenamine201720205.3low000030
dv 1006201720205.3medium000030
climbazolearomatic ether;
hemiaminal ether;
imidazoles;
ketone;
monochlorobenzenes
201720205.3low000030
triadimenolaromatic ether;
conazole fungicide;
hemiaminal ether;
monochlorobenzenes;
secondary alcohol;
triazole fungicide
antifungal agrochemical;
EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor;
xenobiotic metabolite
201720205.3medium000030
amonafideisoquinolines201720205.3low000030
flupirtineaminopyridine201720205.3low000030
chaetochromin201720205.3medium000030
enoximonearomatic ketone201720205.3low000030
aripiprazolearomatic ether;
delta-lactam;
dichlorobenzene;
N-alkylpiperazine;
N-arylpiperazine;
quinolone
drug metabolite;
H1-receptor antagonist;
second generation antipsychotic;
serotonergic agonist
201720205.3low000030
aloxistatinepoxide;
ethyl ester;
L-leucine derivative;
monocarboxylic acid amide
anticoronaviral agent;
cathepsin B inhibitor
201920195.0low000010
indocate201720205.3medium000030
N(4)-acetylsulfathiazole1,3-thiazoles;
acetamides;
sulfonamide
marine xenobiotic metabolite201720205.3high000030
cyclizine hydrochloride201720205.5medium000020
2,3-trimethylene-4-quinazolonequinazolines201720205.3medium000030
1,3-dimethyluric acidoxopurinemetabolite201720205.3low000030
danofloxacinquinolines201720205.3low000030
nitrefazoleimidazoles201720205.3medium000030
methotrimeprazinephenothiazines;
tertiary amine
anticoronaviral agent;
cholinergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
non-narcotic analgesic;
phenothiazine antipsychotic drug;
serotonergic antagonist
201720205.3low000030
honokiolbiphenyls201720205.3low000030
9-methoxyellipticine201720205.3low000030
3-aminophenoxazonephenoxazine201720205.3low000030
3-deazaneplanocin201720205.3low000030
tryptanthrinealkaloid antibiotic;
organic heterotetracyclic compound;
organonitrogen heterocyclic compound
201720205.3low000030
2-chlorodiazepam201720205.3medium000030
Polycartine Bphenazines201720205.3high000030
aminoquinuride dihydrochloride201720205.3high000030
thioproperazine mesylatephenothiazines201720205.3medium000030
n(6)-(delta(2)-isopentenyl)adenine6-isopentenylaminopurinecytokinin201720205.3low000030
4-methyl-N-(phenylmethyl)benzenesulfonamidesulfonamide201720205.3medium000030
zpck201920204.5low000020
sr141716amidopiperidine;
carbohydrazide;
dichlorobenzene;
monochlorobenzenes;
pyrazoles
anti-obesity agent;
appetite depressant;
CB1 receptor antagonist
201720205.3low000030
(6R)-7-[4-(dimethylamino)phenyl]-N-hydroxy-4,6-dimethyl-7-oxohepta-2,4-dienamidearomatic ketone201720205.5high000020
fingolimodaminodiol;
primary amino compound
antineoplastic agent;
CB1 receptor antagonist;
immunosuppressive agent;
prodrug;
sphingosine-1-phosphate receptor agonist
201720205.3low000030
tesmilifenediarylmethane201720205.3low000030
sr 27897indolyl carboxylic acid201720205.3low000030
n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamineleucine derivative201720205.3low000030
norketamineorganochlorine compound201720205.3low000030
indatralineindanes201920204.5low000020
methotrexatedicarboxylic acid;
monocarboxylic acid amide;
pteridines
abortifacient;
antimetabolite;
antineoplastic agent;
antirheumatic drug;
dermatologic drug;
DNA synthesis inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
immunosuppressive agent
201720205.3low000030
salvinorin aorganic heterotricyclic compound;
organooxygen compound
metabolite;
oneirogen
201920195.0low000010
4-diethoxyphosphorylmethyl-n-(4-bromo-2-cyanophenyl)benzamide201720205.3low000030
n,n-di-n-hexyl-2-(4-fluorophenyl)indole-3-acetamidephenylindole201720205.3low000030
l 741626piperidines201720205.3low000030
dx 8951pyranoindolizinoquinoline201720205.3low000030
tipifarnibimidazoles;
monochlorobenzenes;
primary amino compound;
quinolone
antineoplastic agent;
apoptosis inducer;
EC 2.5.1.58 (protein farnesyltransferase) inhibitor
201720205.3low000030
cyc 2022,6-diaminopurinesantiviral drug;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
201720205.3low000030
avasimibemonoterpenoid201720205.3low000030
l 163191201720205.3low000030
dizocilpinesecondary amino compound;
tetracyclic antidepressant
anaesthetic;
anticonvulsant;
neuroprotective agent;
nicotinic antagonist;
NMDA receptor antagonist
201720205.3low000030
s-benzylcysteineS-aryl-L-cysteine zwitterion201720205.3high000030
chelidoninealkaloid antibiotic;
alkaloid fundamental parent;
benzophenanthridine alkaloid
201720205.3low000030
lapatinibfurans;
organochlorine compound;
organofluorine compound;
quinazolines
antineoplastic agent;
tyrosine kinase inhibitor
201720205.3low000030
roxindoleindolesalpha-adrenergic antagonist;
serotonergic drug
201720205.3low000030
conidendrin201720205.3high000030
Porfiromycinemitomycin201720205.3high000030
nsc 953971,4-naphthoquinones201720205.3low000030
4-methyl-2-quinazolinamine201720205.3high000030
2-glycineamide-5-chlorophenyl-2-pyrryl ketone201720205.3high000030
niguldipine hydrochloride201920204.5medium000020
2,5-bis(5-hydroxymethyl-2-thienyl)furanthiophenes201720205.3low000030
ritonavir1,3-thiazoles;
carbamate ester;
carboxamide;
L-valine derivative;
ureas
antiviral drug;
environmental contaminant;
HIV protease inhibitor;
xenobiotic
201720205.3low000030
bardoxolone methylcyclohexenones201920195.0low000010
Destruxin Bcyclodepsipeptide201720205.3high000030
tosylphenylalanyl chloromethyl ketonealpha-chloroketone;
sulfonamide
alkylating agent;
serine proteinase inhibitor
201720205.3low000030
trichostatin aantibiotic antifungal agent;
hydroxamic acid;
trichostatin
bacterial metabolite;
EC 3.5.1.98 (histone deacetylase) inhibitor;
geroprotector
201920195.0low000010
sitafloxacinfluoroquinolone antibiotic;
quinolines;
quinolone antibiotic
201920195.0low000010
2'-c-methylcytidine201720205.3low000030
jp-1302201720205.3medium000030
7-chloro-5,10-dihydrothieno[3,4-b][1,5]benzodiazepin-4-onebenzodiazepine201720205.3high000030
tenatoprazoleimidazopyridine201720205.3low000030
s 1033(trifluoromethyl)benzenes;
imidazoles;
pyridines;
pyrimidines;
secondary amino compound;
secondary carboxamide
anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor
201720205.3low000030
5-[(2-fluoroanilino)methyl]-8-quinolinolhydroxyquinoline201720205.3high000030
benidipine hydrochloride201720205.5low000020
benidipine201920195.0low000010
2-(1,3-benzoxazol-2-ylamino)-5-spiro[1,6,7,8-tetrahydroquinazoline-4,1'-cyclopentane]onequinazolines201720205.3high000030
chlorprothixenechlorprothixene201720205.3medium000030
jrf 12201720205.3low000030
5-amino-3-(4-methoxyphenyl)-4-oxo-1-thieno[3,4-d]pyridazinecarboxylic acid ethyl estermethoxybenzenes;
substituted aniline
201720205.3high000030
3-hydroxypyridine, sodium salt201720205.3high000030
N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-1-naphthalenecarboxamidenaphthalenecarboxamide201720205.3medium000030
5-[(2-bromoanilino)methyl]-8-quinolinolhydroxyquinoline201720205.3high000030
3-amino-n-(4-methoxybenzyl)-4,6-dimethylthieno(2,3-b)pyridine-2-carboxamide201720205.3medium000030
N-[(2-methoxyphenyl)methyl]-4-(1-piperidinyl)anilinearomatic amine201720205.3high000030
1-[4-(4-bromophenyl)-2-thiazolyl]-4-piperidinecarboxamidepiperidinecarboxamide201720205.3high000030
5-[[2-(trifluoromethyl)anilino]methyl]-8-quinolinolhydroxyquinoline201720205.3high000030
N-[3-[2-[(4-methyl-2-pyridinyl)amino]-4-thiazolyl]phenyl]acetamideacetamides;
anilide
201720205.3high000030
5-bromo-N-(5-cyclohexyl-1,3,4-thiadiazol-2-yl)-2-thiophenecarboxamidearomatic amide;
thiophenes
201720205.3high000030
6-amino-1-[2-(3,4-dimethoxyphenyl)ethyl]-2-sulfanylidene-4-pyrimidinonedimethoxybenzene201720205.3high000030
N-[4-[(3,4-dimethyl-5-isoxazolyl)sulfamoyl]phenyl]-6,8-dimethyl-2-(2-pyridinyl)-4-quinolinecarboxamidearomatic amide201720205.3high000030
N-[5-[(4-chlorophenoxy)methyl]-1,3,4-thiadiazol-2-yl]-5-methyl-3-phenyl-4-isoxazolecarboxamidearomatic ether201720205.3high000030
3-chloro-1-(2,5-dimethoxyphenyl)-4-(1-piperidinyl)pyrrole-2,5-dionemaleimides201720205.3high000030
Src Inhibitor-1aromatic ether;
polyether;
quinazolines;
secondary amino compound
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor201720205.3high000030
1-[2-(3,4-dimethoxyphenyl)ethyl]-6-propyl-2-sulfanylidene-7,8-dihydro-5H-pyrimido[4,5-d]pyrimidin-4-onedimethoxybenzene201720205.3high000030
2-phenyl-N-[4-(2-thiazolylsulfamoyl)phenyl]-4-quinolinecarboxamidequinolines201720205.3high000030
3-(2,5-dimethyl-1-phenyl-3-pyrrolyl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepinepyrroles201720205.3high000030
bi-78d3aryl sulfide201720205.3medium000030
kartogenin201720205.3low000030
toremifenearomatic ether;
organochlorine compound;
tertiary amine
antineoplastic agent;
bone density conservation agent;
estrogen antagonist;
estrogen receptor modulator
201920195.0low000010
vx-745aryl sulfide;
dichlorobenzene;
difluorobenzene;
pyrimidopyridazine
anti-inflammatory drug;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
201720205.3low000030
dasatinib1,3-thiazoles;
aminopyrimidine;
monocarboxylic acid amide;
N-(2-hydroxyethyl)piperazine;
N-arylpiperazine;
organochlorine compound;
secondary amino compound;
tertiary amino compound
anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor
201720205.3low000030
zd 6474aromatic ether;
organobromine compound;
organofluorine compound;
piperidines;
quinazolines;
secondary amine
antineoplastic agent;
tyrosine kinase inhibitor
201720205.3low000030
N-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamideindoles201920204.5high000020
nih-12848201720205.3high000030
2,4-dioxo-3-pentyl-N-[3-(1-piperidinyl)propyl]-1H-quinazoline-7-carboxamidequinazolines201720205.3high000030
[1-(3-methylphenyl)-5-benzimidazolyl]-(1-piperidinyl)methanonebenzimidazoles201720205.3high000030
2-[[(6-bromo-1H-imidazo[4,5-b]pyridin-2-yl)thio]methyl]benzonitrileimidazopyridine201720205.3high000030
3-[(3-fluorophenyl)methyl]-8-[4-(4-fluorophenyl)-4-oxobutyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-onearomatic ketone201720205.3high000030
4-[[7-[(4-fluorophenyl)methyl]-1,3-dimethyl-2,6-dioxo-8-purinyl]methyl]-1-piperazinecarboxylic acid ethyl esteroxopurine201720205.3high000030
N,N-dimethylcarbamodithioic acid (1-acetamido-2,2,2-trichloroethyl) esterorganonitrogen compound;
organosulfur compound
201720205.3high000030
6-bromo-2-(4-methylphenyl)-N-[(1-methyl-4-pyrazolyl)methyl]-4-quinolinecarboxamidequinolines201720205.3high000030
LSM-1924organic heterotricyclic compound;
organooxygen compound
201720205.3high000030
ferrostatin-1ethyl ester;
primary arylamine;
substituted aniline
antifungal agent;
antioxidant;
ferroptosis inhibitor;
neuroprotective agent;
radiation protective agent;
radical scavenger
201720205.3low000030
6-(2-methyl-1-piperidinyl)-5-nitro-4-pyrimidinamineC-nitro compound201720205.3high000030
rabeprazole(1-)organic nitrogen anion201920204.5high000020
ncgc00099374201720205.3high000030
2-nitro-4-[(6-nitro-4-quinolinyl)amino]-N-[4-(pyridin-4-ylamino)phenyl]benzamidebenzamides201720205.3high000030
luteolin3'-hydroxyflavonoid;
tetrahydroxyflavone
angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
c-Jun N-terminal kinase inhibitor;
EC 2.3.1.85 (fatty acid synthase) inhibitor;
immunomodulator;
nephroprotective agent;
plant metabolite;
radical scavenger;
vascular endothelial growth factor receptor antagonist
201720205.3low000030
cyclosporine201920195.0low000010
kaempferol7-hydroxyflavonol;
flavonols;
tetrahydroxyflavone
antibacterial agent;
geroprotector;
human blood serum metabolite;
human urinary metabolite;
human xenobiotic metabolite;
plant metabolite
201720205.3low000030
genistein7-hydroxyisoflavonesantineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
geroprotector;
human urinary metabolite;
phytoestrogen;
plant metabolite;
tyrosine kinase inhibitor
201720205.3low000030
mycophenolate mofetilcarboxylic ester;
ether;
gamma-lactone;
phenols;
tertiary amino compound
anticoronaviral agent;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
immunosuppressive agent;
prodrug
201720205.3medium000030
bruceantintriterpenoid201720205.3low000030
chrysin7-hydroxyflavonol;
dihydroxyflavone
anti-inflammatory agent;
antineoplastic agent;
antioxidant;
EC 2.7.11.18 (myosin-light-chain kinase) inhibitor;
hepatoprotective agent;
plant metabolite
201720205.3low000030
daidzein7-hydroxyisoflavonesantineoplastic agent;
EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
phytoestrogen;
plant metabolite
201720205.3low000030
neticonazolearomatic ether;
benzenes;
conazole antifungal drug;
enamine;
imidazole antifungal drug;
imidazoles;
methyl sulfide
antifungal drug;
EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor
201720205.3medium000030
N-(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoylethanolamineendocannabinoid;
N-acylethanolamine 22:6
201720205.3medium000030
n-oleoylethanolamineendocannabinoid;
N-(long-chain-acyl)ethanolamine;
N-acylethanolamine 18:1
EC 3.5.1.23 (ceramidase) inhibitor;
geroprotector;
PPARalpha agonist
201720205.3low000030
alpha-zearalenolmacrolide201720205.3high000030
su 9516201720205.3low000030
N-(4-bromo-3-methylphenyl)-2,5-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-aminetriazolopyrimidines201720205.3high000030
sb 277011201720205.3low000030
sb 223412201720205.3low000030
sr 59230atetralins201720205.3high000030
3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamidepyrimidines201720205.3medium000030
kn 62piperazines201720205.3low000030
MeJAJasmonate derivatives201720205.3high000030
1h-pyrrole-2,5-dione, 3-(1-methyl-1h-indol-3-yl)-4-(1-methyl-6-nitro-1h-indol-3-yl)-201720205.3high000030
pd 161570201720205.3medium000030
su 11248monocarboxylic acid amide;
pyrroles
angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
immunomodulator;
neuroprotective agent;
vascular endothelial growth factor receptor antagonist
201720177.0low000010
palbociclibaminopyridine;
aromatic ketone;
cyclopentanes;
piperidines;
pyridopyrimidine;
secondary amino compound;
tertiary amino compound
antineoplastic agent;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
201720205.3low000030
jnj-7706621sulfonamide201720205.3low000030
virginiamycin factor s1cyclodepsipeptide;
macrolide antibiotic
antibacterial drug;
bacterial metabolite
201720205.3high000030
fenoterolhydrobromidebeta-adrenergic agonist;
bronchodilator agent;
sympathomimetic agent
201920204.5low000020
xib 4035201720205.3high000030
gw-5074201920195.0low000010
belotecanpyranoindolizinoquinoline201720205.3low000030
norgestimateketoxime;
steroid ester;
terminal acetylenic compound
contraceptive drug;
progestin;
synthetic oral contraceptive
201720205.3high000030
b 43aromatic amine;
aromatic ether;
cyclopentanes;
primary amino compound;
pyrrolopyrimidine
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
geroprotector
201720205.3medium000030
4-(2' methoxyphenyl)-1-(2'-(n-(2''-pyridinyl)-4-fluorobenzamido)ethyl)piperazine201720205.3medium000030
methiazolebenzimidazoles;
carbamate ester
201720205.3high000030
sb 218795quinolines201720205.3medium000030
bvt.948201720205.3high000030
fk 866benzamides;
N-acylpiperidine
201920195.0low000010
a 38503201720205.3medium000030
parthenolidesesquiterpene lactonedrug allergen;
inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
peripheral nervous system drug
201720196.0medium000020
krn 633201720205.3medium000030
5-amino-4-oxo-3-phenyl-1-thieno[3,4-d]pyridazinecarboxylic acidorganonitrogen heterocyclic compound;
organosulfur heterocyclic compound
201720205.3high000030
gw 5015161,3-thiazoles;
aromatic ether;
aryl sulfide;
monocarboxylic acid;
organofluorine compound
carcinogenic agent;
PPARbeta/delta agonist
201720205.3low000030
dolastatin 101,3-thiazoles;
tetrapeptide
animal metabolite;
antineoplastic agent;
apoptosis inducer;
marine metabolite;
microtubule-destabilising agent
201720205.3low000030
spc-839201720205.3low000030
midostaurinbenzamides;
gamma-lactam;
indolocarbazole;
organic heterooctacyclic compound
antineoplastic agent;
EC 2.7.11.13 (protein kinase C) inhibitor
201720205.3low000030
valnemulin201920204.5medium000020
nu 7026organic heterotricyclic compound;
organooxygen compound
201720205.3low000030
osi 930aromatic amide201720205.3medium000030
ticagreloraryl sulfide;
hydroxyether;
organofluorine compound;
secondary amino compound;
triazolopyrimidines
P2Y12 receptor antagonist;
platelet aggregation inhibitor
201720205.3low000030
l 692585peptide201720205.3high000030
pi103aromatic amine;
morpholines;
organic heterotricyclic compound;
phenols;
tertiary amino compound
antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor
201720205.3low000030
nnc 26-9100aminopyridine201720205.3medium000030
2-(3-chlorobenzyloxy)-6-(piperazin-1-yl)pyrazine201720205.3high000030
tivozanibaromatic ether201720205.3low000030
hki 272nitrile;
quinolines
antineoplastic agent;
tyrosine kinase inhibitor
201920195.0low000010
n-(6-chloro-7-methoxy-9h-beta-carbolin-8-yl)-2-methylnicotinamide201720205.3medium000030
tae226morpholines201720205.3low000030
gw0742monocarboxylic acid201720205.3low000030
u 18666ahydrochlorideantiviral agent;
EC 1.3.1.72 (Delta(24)-sterol reductase) inhibitor;
Hedgehog signaling pathway inhibitor;
nicotinic antagonist;
sterol biosynthesis inhibitor
201720205.3low000030
sb 525334quinoxaline derivative201720205.3low000030
bx795ureas201720205.3low000030
azd 6244benzimidazoles;
bromobenzenes;
hydroxamic acid ester;
monochlorobenzenes;
organofluorine compound;
secondary amino compound
anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
201720205.3low000030
1-(2-(1-adamantyl)ethyl)-1-pentyl-3-(3-(4-pyridyl)propyl)urea201720205.3medium000030
bay 61-3606pyrimidines201720205.3medium000030
sd-208201720205.3low000030
crenolanibaminopiperidine;
aromatic ether;
benzimidazoles;
oxetanes;
quinolines;
tertiary amino compound
angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
201720205.3low000030
cj 033466201720205.3high000030
cc 401pyrazoles;
ring assembly
201720205.3medium000030
PB28aromatic ether;
piperazines;
tetralins
anticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
sigma-2 receptor agonist
201720205.3low000030
arterolane201720205.3low000030
cariprazine201720205.3low000030
krp-203201720205.3high000030
regorafenib(trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
phenylureas;
pyridinecarboxamide
antineoplastic agent;
hepatotoxic agent;
tyrosine kinase inhibitor
201720205.3low000030
at 7867monochlorobenzenes;
piperidines;
pyrazoles
antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
201720205.3high000030
acetic acid 2-[4-methyl-8-(4-morpholinylsulfonyl)-1,3-dioxo-2-pyrrolo[3,4-c]quinolinyl]ethyl esterpyrroloquinoline201720205.3high000030
ptc 124oxadiazole;
ring assembly
201720205.3low000030
degrasyn201920204.5low000020
bi 2536201720205.3low000030
azd 1152anilide;
monoalkyl phosphate;
monofluorobenzenes;
pyrazoles;
quinazolines;
secondary amino compound;
secondary carboxamide;
tertiary amino compound
antineoplastic agent;
Aurora kinase inhibitor;
prodrug
201720205.3medium000030
carfilzomibepoxide;
morpholines;
tetrapeptide
antineoplastic agent;
proteasome inhibitor
201720205.3low000030
idelalisibaromatic amine;
organofluorine compound;
purines;
quinazolines;
secondary amino compound
antineoplastic agent;
apoptosis inducer;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
201720205.3low000030
motesanibpyridinecarboxamide201720205.3medium000030
pf-562,271indoles201720205.3medium000030
gliocladin c201720205.3high000030
ku-0060648dibenzothiophenes201720205.3medium000030
bgt226aromatic ether;
imidazoquinoline;
N-arylpiperazine;
organofluorine compound;
pyridines
antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor
201720205.3medium000030
n-desmethyldanofloxacin201720205.3high000030
rabeprazole sodiumorganic sodium salt201720177.0low000010
azd 1152-hqpaanilide;
monofluorobenzenes;
primary alcohol;
pyrazoles;
quinazolines;
secondary amino compound;
secondary carboxamide;
tertiary amino compound
antineoplastic agent;
Aurora kinase inhibitor
201920204.5low000020
CDN1163aromatic ether;
quinolines;
secondary carboxamide
SERCA activator201720205.3medium000030
gsk 269962a201720205.3medium000030
pha 848125201720205.3medium000030
nvp-bhg712benzamides201720205.3medium000030
pf 04217903quinolines201720205.3medium000030
5-[[4-(4-acetylphenyl)-1-piperazinyl]sulfonyl]-1,3-dihydroindol-2-onearomatic ketone201720205.3high000030
ph 797804aromatic ether;
benzamides;
organobromine compound;
organofluorine compound;
pyridone
anti-inflammatory agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
201720205.3low000030
srt1720201720205.3low000030
purfalcamine201720205.3high000030
bms 754807pyrazoles;
pyridines;
pyrrolidines;
pyrrolotriazine
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
201720205.3low000030
ponatinib(trifluoromethyl)benzenes;
acetylenic compound;
benzamides;
imidazopyridazine;
N-methylpiperazine
antineoplastic agent;
tyrosine kinase inhibitor
201720205.3low000030
quizartinibbenzoimidazothiazole;
isoxazoles;
morpholines;
phenylureas
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
necroptosis inhibitor
201720205.3low000030
PP121aromatic amine;
cyclopentanes;
pyrazolopyrimidine;
pyrrolopyridine
antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
tyrosine kinase inhibitor
201720205.3medium000030
navitoclaxaryl sulfide;
monochlorobenzenes;
morpholines;
N-sulfonylcarboxamide;
organofluorine compound;
piperazines;
secondary amino compound;
sulfone;
tertiary amino compound
antineoplastic agent;
apoptosis inducer;
B-cell lymphoma 2 inhibitor
201720205.3low000030
gsk 650394phenylpyridine201720205.3medium000030
dcc-2036organofluorine compound;
phenylureas;
pyrazoles;
pyridinecarboxamide;
quinolines
tyrosine kinase inhibitor201720205.3medium000030
cabozantinibaromatic ether;
dicarboxylic acid diamide;
organofluorine compound;
quinolines
antineoplastic agent;
tyrosine kinase inhibitor
201720205.3low000030
TAK-5801,3-thiazolecarboxamide;
aminopyrimidine;
chloropyridine;
organofluorine compound;
pyrimidinecarboxamide;
secondary carboxamide
antineoplastic agent;
apoptosis inducer;
B-Raf inhibitor
201720205.3medium000030
8-(4-aminophenyl)-2-(4-morpholinyl)-1-benzopyran-4-onechromones201720205.3high000030
pf 3758309organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound
201720205.3low000030
(5-(2,4-bis((3s)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanolbenzyl alcohols;
morpholines;
pyridopyrimidine;
tertiary amino compound
antineoplastic agent;
apoptosis inducer;
mTOR inhibitor
201920204.5low000020
5-(2-benzofuranyl)-4-[(1-methyl-5-tetrazolyl)thio]thieno[2,3-d]pyrimidinearyl sulfide;
thienopyrimidine
201720205.3high000030
5-(3-methylsulfonylphenyl)-4-[(1-methyl-5-tetrazolyl)thio]thieno[2,3-d]pyrimidinearyl sulfide;
thienopyrimidine
201720205.3high000030
5-bromo-4-[(1-methyl-5-tetrazolyl)thio]thieno[2,3-d]pyrimidinearyl sulfide;
thienopyrimidine
201720205.3high000030
baricitinibazetidines;
nitrile;
pyrazoles;
pyrrolopyrimidine;
sulfonamide
anti-inflammatory agent;
antirheumatic drug;
antiviral agent;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
immunosuppressive agent
201720205.3low000030
6-(1,3-benzodioxol-5-yl)-N-methyl-N-(thiophen-2-ylmethyl)-4-quinazolinaminequinazolines201720205.3high000030
6-[(3-aminophenyl)methyl]-4-methyl-2-methylsulfinyl-5-thieno[3,4]pyrrolo[1,3-d]pyridazinoneorganic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound
201720205.3medium000030
N-[(5-bromo-8-hydroxy-7-quinolinyl)-thiophen-2-ylmethyl]acetamidehydroxyquinoline201720205.3high000030
p505-15201720205.3high000030
mrt67307aromatic amine201720205.3medium000030
N-[3-[[5-chloro-2-[4-(4-methyl-1-piperazinyl)anilino]-4-pyrimidinyl]oxy]phenyl]-2-propenamidepiperazines201720205.3high000030
ribociclib201720205.3low000030
1-[3-[4-[(1-methyl-5-tetrazolyl)thio]-5-thieno[2,3-d]pyrimidinyl]phenyl]ethanonearomatic ketone;
thienopyrimidine
201720205.3high000030
pha 793887piperidinecarboxamide201720205.3high000030
gsk 2334470indazoles201920195.0low000010
ml228 probe1,2,4-triazines;
biphenyls;
pyridines;
secondary amino compound
hypoxia-inducible factor pathway activator201720205.3high000030
pf-03882845201720205.3high000030
jq1 compoundcarboxylic ester;
organochlorine compound;
tert-butyl ester;
thienotriazolodiazepine
angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
bromodomain-containing protein 4 inhibitor;
cardioprotective agent;
ferroptosis inducer
201720205.3low000030
pf-04620110201720205.3medium000030
gsk525762abenzodiazepine201720205.3low000030
birinapantdipeptide201920195.0low000010
torin 1N-acylpiperazine;
N-arylpiperazine;
organofluorine compound;
pyridoquinoline;
quinolines
antineoplastic agent;
mTOR inhibitor
201720205.3medium000030
abt-199aromatic ether;
C-nitro compound;
monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
N-sulfonylcarboxamide;
oxanes;
pyrrolopyridine
antineoplastic agent;
apoptosis inducer;
B-cell lymphoma 2 inhibitor
201720205.3low000030
1-[4-fluoro-3-(trifluoromethyl)phenyl]-3-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)ureaureas201720205.3medium000030
N-(4-methyl-2-pyridinyl)-4-[3-(trifluoromethyl)anilino]-1-piperidinecarbothioamide(trifluoromethyl)benzenes201720205.3high000030
ncgc00242364quinazolines201720205.3high000030
gsk1210151aimidazoquinoline201720205.3low000030
hs-173201720205.3high000030
sr1664indolecarboxamide201720205.3high000030
4-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-n-(4-methoxypyridin-2-yl)piperazine-1-carbothioamide201720205.3high000030
N-[4-(1-benzoyl-4-piperidinyl)butyl]-3-(3-pyridinyl)-2-propenamidebenzamides;
N-acylpiperidine
201720205.5high000020
N-[4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamideaminoquinoline201720205.5high000020
cudc-907201720205.3low000030
methacycline201920195.0low000010
methacycline monohydrochloride201720205.5low000020
2-[[[4-hydroxy-2-oxo-1-(phenylmethyl)-3-quinolinyl]-oxomethyl]amino]acetic acidquinolines201720205.3high000030
agi-5198201720205.3low000030
cep-32496201720205.3medium000030
epz004777N-glycosyl compound201720205.3low000030
3-[[2-(2-pyridinyl)-6-(1,2,4,5-tetrahydro-3-benzazepin-3-yl)-4-pyrimidinyl]amino]propanoic acidorganonitrogen heterocyclic compound201720205.3medium000030
entecavirbenzamides;
N-acylpiperidine
201720205.3medium000030
gkt137831201720205.3low000030
vx-509201720205.3high000030
vx-970sulfonamide201720205.3low000030
gs-9973201720205.3high000030
amg 925201720205.3high000030
gne-618201720205.3high000030
g007-lk201720205.3medium000030
volitinib201720205.3high000030
ML355benzothiazoles;
monomethoxybenzene;
phenols;
secondary amino compound;
substituted aniline;
sulfonamide
EC 1.13.11.31 (arachidonate 12-lipoxygenase) inhibitor;
platelet aggregation inhibitor
201720205.3high000030
acp-196aromatic amine;
benzamides;
imidazopyrazine;
pyridines;
pyrrolidinecarboxamide;
secondary carboxamide;
tertiary carboxamide;
ynone
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
201720205.3low000030
gsk343aminopyridine;
indazoles;
N-alkylpiperazine;
N-arylpiperazine;
pyridone;
secondary carboxamide
antineoplastic agent;
apoptosis inducer;
EC 2.1.1.43 (enhancer of zeste homolog 2) inhibitor
201720205.3low000030
agi-6780201720205.3medium000030
khs101201720205.3medium000030
cb-839201720205.3low000030
gsk-j4organonitrogen heterocyclic compound201720205.3low000030
pf-06424439201720205.3high000030
etp-46464201720205.3high000030
onc201201720205.3low000030
kai407201720205.3high000030
6,7-dimethoxy-2-(pyrrolidin-1-yl)-n-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine201720205.3high000030
enasidenib1,3,5-triazines;
aminopyridine;
aromatic amine;
organofluorine compound;
secondary amino compound;
tertiary alcohol
antineoplastic agent;
EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor
201720205.3low000030
oicr-9429201720205.3medium000030
lly-507201720205.3medium000030
at 9283201720205.3medium000030
hypoxanthinenucleobase analogue;
oxopurine;
purine nucleobase
fundamental metabolite201720205.3low000030
clozapinebenzodiazepine;
N-arylpiperazine;
N-methylpiperazine;
organochlorine compound
adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
GABA antagonist;
histamine antagonist;
muscarinic antagonist;
second generation antipsychotic;
serotonergic antagonist;
xenobiotic
201720205.3low000030
1-hydroxyphenazinephenazines201720205.3low000030
ro 24-7429benzodiazepine201720205.3medium000030
nintedanib201720205.3low000030
n'-(3,4-dihydroxybenzylidene)-3-hydroxy-2-naphthahydrazidecatechols;
hydrazide;
hydrazone;
naphthols
EC 3.6.5.5 (dynamin GTPase) inhibitor201720205.3high000030
ver 52296aromatic amide;
isoxazoles;
monocarboxylic acid amide;
morpholines;
resorcinols
angiogenesis inhibitor;
antineoplastic agent;
Hsp90 inhibitor
201720205.3low000030
rvx 208201720205.3low000030
bmn 673201720205.3low000030
ConditionIndicatedStudiesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
Congenital Zika Syndrome0202020204.0high000010
Disease Models, Animal0202020204.0high000010
Zika Virus Infection0202020204.0high000010

Bioavailability (2)

ArticleYear
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Molecular pharmacology, , Volume: 96, Issue:5
2019
Highly predictive and interpretable models for PAMPA permeability.
Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3
2017